In combination with different amount of EphA4 reduction and assessing the cell-specific contribution to disease, our findings suggest that lowering EphA4 expression as target in ALS may suffer from a complex therapeutic time window. Here, EPHA4 is linked to amyotrophic lateral sclerosis.